Immunotherapy | CHOP Research Institute
 

Immunotherapy

Published on
Mar 18, 2024
Learn how the NAD metabolite controls how well T and B cells can detect their antigens, leading to quicker immune responses.
Published on
Mar 5, 2024
Two global teams are developing solid cancer drugs and understanding T-cell receptors.
Published on
Jan 29, 2024
With funding from the National Cancer Institute’s Childhood Cancer Data Initiative, CHOP researchers are identifying new immunotherapy targets.
Published on
Dec 28, 2023
These six stories received the highest number of engagements on CHOP Research social media channels in 2023.
Published on
Nov 20, 2023
The NIH-funded study, PRESCRIBE, will help researchers understand how antibiotics affect organ function recovery and respiratory microbiota in children with sepsis.
Published on
Sep 8, 2023
Sarah K. Tasian, MD, received a $1 million grant to further her research into a novel immunotherapy for high-risk pediatric leukemias.
Published on
Jul 7, 2023
See highlights from the Third Annual Lymphatic Disorder Conference and Cellicon Valley ’23, and more in this week’s research news roundup.
Published on
Jun 23, 2023
U.S. News & World Report ranks CHOP No. 1 in region, and we’re proud to have eight specialties ranked in the top five.
Published on
May 26, 2023
In this week’s news roundup, CHOP’s Department of Pediatrics ranked No 1. in U.S. News & World Report’s ‘Best Pediatrics Programs’ for medical schools.

Dr. Wolpaw’s laboratory seeks to develop an understanding of how tumor heterogeneity and epigenetics impact inflammatory signaling and immunotherapy responses in pediatric solid tumors with a goal of developing more efficacious, less toxic therapies to treat these devastating diseases.